University of Pittsburgh researchers have engineered a next-generation soluble CD4-D1 domain with enhanced stability and extended in vivo half-life, designed to serve as a potent HIV entry inhibitor.
Researchers at Pitt have developed a rectal microbicide product in the form of a hypotonic liquid enema containing the antiretroviral drug tenofovir (TFV) for HIV prevention.
University of Pittsburgh researchers have developed a sustained release vaginal film for the simultaneous protection against HIV and unintended pregnancy.